Visen Pharmaceuticals 6M FY26 net loss narrows 11.79% to RMB 104.1 million; revenue turns to RMB 34.54 million

• Visen Pharmaceuticals posted revenue of RMB 34.54 million for the six months ended June 30, 2026, swinging from no revenue a year earlier.
• Net loss narrowed 11.79% to RMB 104.1 million; loss per share improved to RMB 0.95 from RMB 1.18.
• Gross profit was RMB 18.06 million, with gross margin of about 52% on cost of sales of RMB 16.48 million.
• R&D costs fell 19.85% to RMB 37.37 million on completed registration and major clinical activities; administrative expenses dropped 44.05% to RMB 33.6 million on reclassification.
• Cash and cash equivalents declined to RMB 505.81 million from RMB 632.65 million at end-2025; first commercial prescription for lonapegsomatropin was issued in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12325777), on September 09, 2026, and is solely responsible for the information contained therein.